BioSpace News Archive

Nasal Administration of Foralumab is a potentially transformative approach for treating patients with Covid-19

Agendia, Inc., a world leader in precision oncology for breast cancer, presented data at the European Society for Medical Oncology Virtual Congress 2020 showing that MammaPrint’s Ultra-Low risk threshold can identify postmenopausal breast cancer patients who will have an excellent prognosis with limited or no tamoxifen treatment.

Step-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit to PD-1 inhibitor therapy

Focusing on transformation into a commercial stage biopharmaceutical company and the potential of its unique antibody-cleaving enzyme platform beyond transplantation in areas such as autoimmunity and gene therapy

Triplet Combination Demonstrates Encouraging Anti-Tumor Activity and Tolerability in Recurrent Platinum-Sensitive Ovarian Cancer

Biofidelity Ltd, the cancer diagnostics company, announces the appointment of Stephen Miller as Chief Commercial Officer, based in the US. Following Biofidelity’s recent $12m Series A financing, supported by experienced investors BlueYard Capital, Longwall Ventures and Agilent Technologies, the Company is now focused on expanding its executive team, a critical step in its commercial strategy.

Akerna (Nasdaq: KERN), an enterprise software, leading compliance technology provider and developer of the cannabis industry’s first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), will report financial results for its fourth quarter and fiscal year ended June 30, 2020 on Thursday September 24, 2020.

Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the U.S. Food and Drug Administration (FDA) has recently granted Orphan Drug designation to Toripalimab for the treatment of soft tissue sarcoma.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the first reported data from RATIONALE 304, the Phase 3 trial of its anti-PD-1 antibody tislelizumab in combination with chemotherapy as a potential first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)

Ufovax, LLC, (Ufovax), a vaccine biotechnology company based on the patented One-component Self-Assembling protein NanoParticle® (1c-SApNP®) vaccine design and manufacturing platform invented by Associate Professor Jiang Zhu, PhD, of Scripps Research (La Jolla, CA), announced the advancement toward Phase I clinical trials of its next-generation SARS-CoV-2